Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 1/20 | 0.46 |
| ▸ | GABRA5 | P31644 | 3/20 | 0.40 |
| ▸ | GPR119 | Q8TDV5 | 9/20 | 0.39 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.37 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.37 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.37 |
| ▸ | FPR2 | P25090 | 1/20 | 0.36 |
| ▸ | IDO1 | P14902 | 1/20 | 0.36 |
| ▸ | TDO2 | P48775 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20233776 | 0.85 | DGAT1 (0.49) | DGAT1GPR119PRMT5WDR77USP30 | |
| SCHEMBL20129250 | 0.82 | DGAT1 (0.46) | DGAT1GPR119PRMT5WDR77USP30 | |
| SCHEMBL27098082 | 0.81 | DGAT1 (0.45) | DGAT1GPR119PRMT5WDR77USP30 | |
| SCHEMBL27098039 | 0.81 | DGAT1 (0.45) | DGAT1GPR119PRMT5WDR77USP30 | |
| SCHEMBL31401120 | 0.81 | DGAT1 (0.57) | DGAT1GPR119USP30FPR2 | |
| SCHEMBL15525341 | 0.81 | DGAT1 (0.57) | DGAT1GPR119USP30FPR2 | |
| SCHEMBL29547524 | 0.80 | DGAT1 (0.48) | DGAT1GABRA5GPR119PRMT5WDR77 | |
| SCHEMBL27097897 | 0.80 | DGAT1 (0.48) | DGAT1GABRA5GPR119PRMT5WDR77 | |
| SCHEMBL27139797 | 0.80 | DGAT1 (0.48) | DGAT1GABRA5GPR119PRMT5WDR77 | |
| SCHEMBL27097964 | 0.79 | DGAT1 (0.45) | DGAT1GABRA5GPR119USP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11912699-B2 | Tau-protein targeting compounds and associated | ARVINAS OPERATIONS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-11912699-B2 | Tau-protein targeting compounds and associated | ARVINAS OPERATIONS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| WO-2021011913-A1 | TAU-PROTEIN TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. (US) | 2021-01-21 | — | — | WO | disclosed |
| US-20180125821-A1 | TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2018-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11912699-B2 | Tau-protein targeting compounds and associated | MAPT, VHL, CRBN | DGAT1 4519/4885GABRA5 2135/4885GPR119 3791/4885 |
| US-20180125821-A1 | TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE | CRBN, VHL, UBQLN2 | DGAT1 4651/4885GABRA5 2124/4885GPR119 3741/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.